| Arctic Chiropractic & Massage Kodiak | |
|
2975 Mill Bay Rd Ste A Kodiak AK 99615-7831 | |
| (907) 512-0809 | |
| (907) 512-0828 |
| Full Name | Arctic Chiropractic & Massage Kodiak |
|---|---|
| Speciality | Clinic/Center |
| Location | 2975 Mill Bay Rd Ste A, Kodiak, Alaska |
| Authorized Official Name and Position | Christopher Twiford (OFFICE MANAGER) |
| Authorized Official Contact | 9075120809 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Arctic Chiropractic & Massage Kodiak 2975 Mill Bay Rd Ste A Kodiak AK 99615-7831 Ph: (907) 512-0809 | Arctic Chiropractic & Massage Kodiak 2975 Mill Bay Rd Ste A Kodiak AK 99615-7831 Ph: (907) 512-0809 |
| NPI Number | 1558899807 |
|---|---|
| Provider Enumeration Date | 05/31/2017 |
| Last Update Date | 01/10/2018 |
| Medicare PECOS PAC ID | 5294099495 |
|---|---|
| Medicare Enrollment ID | O20180515001824 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558899807 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Provider Name | David Y Prentice |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1366585861 PECOS PAC ID: 9739124793 Enrollment ID: I20050621001000 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | David S Henry |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992090195 PECOS PAC ID: 3476721986 Enrollment ID: I20130312000552 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Sheri Schoenberg |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134282734 PECOS PAC ID: 3476650219 Enrollment ID: I20170316000397 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Grayson Grzegorczyk |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1316451776 PECOS PAC ID: 7416295761 Enrollment ID: I20190211003115 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Laura Homacki |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1285092965 PECOS PAC ID: 6406289685 Enrollment ID: I20191202000540 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Hannah Donadio |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1295111276 PECOS PAC ID: 7012224926 Enrollment ID: I20200409001694 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Brigette Schwimmer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770061319 PECOS PAC ID: 0143574806 Enrollment ID: I20210811002797 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
| Provider Name | Nicholas Larghi |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700361078 PECOS PAC ID: 5597001149 Enrollment ID: I20220422002547 |
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
News Archive
Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
› Verified 2 days ago
Kodiak Area Native Association Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3449 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-9800 Fax: 907-486-9897 | |
North Pacific Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 104 Center Ave, Ste 100, Kodiak, AK 99615 Phone: 907-486-4183 Fax: 907-486-4233 | |
Kodiak Area Native Association Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3449 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-9868 Fax: 907-486-9884 | |
Kodiak Island Medical Associates Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1818 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-6065 Fax: 907-486-2248 | |
Kana Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3449 E Rezanof Dr, Kodiak, AK 99615 Phone: 907-486-9800 Fax: 907-486-9898 | |
Rockmore-king Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Building N46 Cape Sarichef, Kodiak, AK 99619 Phone: 907-487-5757 Fax: 907-487-5360 |